Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Characterization of a human tumorsphere glioma orthotopic model using magnetic resonance imaging.

Wong K, Young GS, Makale M, Hu X, Yildirim N, Cui K, Wong ST, Kesari S.

J Neurooncol. 2011 Sep;104(2):473-81. doi: 10.1007/s11060-010-0517-x. Epub 2011 Jan 15.

2.

Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.

Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E.

Clin Cancer Res. 2011 Feb 1;17(3):459-71. doi: 10.1158/1078-0432.CCR-10-2258. Epub 2010 Dec 13.

3.

Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.

Abdalla MO, Karna P, Sajja HK, Mao H, Yates C, Turner T, Aneja R.

J Control Release. 2011 Feb 10;149(3):314-22. doi: 10.1016/j.jconrel.2010.10.030. Epub 2010 Nov 1.

4.

An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.

Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA, Mazar AP.

Neoplasia. 2010 Oct;12(10):778-88.

5.

A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.

Ahn RW, Chen F, Chen H, Stern ST, Clogston JD, Patri AK, Raja MR, Swindell EP, Parimi V, Cryns VL, O'Halloran TV.

Clin Cancer Res. 2010 Jul 15;16(14):3607-17. doi: 10.1158/1078-0432.CCR-10-0068. Epub 2010 Jun 2.

6.

Modulators of the urokinase-type plasminogen activation system for cancer.

Hildenbrand R, Allgayer H, Marx A, Stroebel P.

Expert Opin Investig Drugs. 2010 May;19(5):641-52. doi: 10.1517/13543781003767400. Review.

PMID:
20402599
7.

Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.

Lin L, Gårdsvoll H, Huai Q, Huang M, Ploug M.

J Biol Chem. 2010 Apr 2;285(14):10982-92. doi: 10.1074/jbc.M109.093492. Epub 2010 Feb 4.

8.

Urokinase plasminogen activator system as a potential target for cancer therapy.

Mekkawy AH, Morris DL, Pourgholami MH.

Future Oncol. 2009 Nov;5(9):1487-99. doi: 10.2217/fon.09.108. Review.

PMID:
19903074
9.

Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment.

Chen H, Pazicni S, Krett NL, Ahn RW, Penner-Hahn JE, Rosen ST, O'Halloran TV.

Angew Chem Int Ed Engl. 2009;48(49):9295-9. doi: 10.1002/anie.200903655. No abstract available.

10.

Receptor-targeted nanoparticles for in vivo imaging of breast cancer.

Yang L, Peng XH, Wang YA, Wang X, Cao Z, Ni C, Karna P, Zhang X, Wood WC, Gao X, Nie S, Mao H.

Clin Cancer Res. 2009 Jul 15;15(14):4722-32. doi: 10.1158/1078-0432.CCR-08-3289. Epub 2009 Jul 7.

11.

Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide.

Chen H, Ahn R, Van den Bossche J, Thompson DH, O'Halloran TV.

Mol Cancer Ther. 2009 Jul;8(7):1955-63. doi: 10.1158/1535-7163.MCT-09-0045. Epub 2009 Jun 30.

12.

Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver.

Van Buren G 2nd, Gray MJ, Dallas NA, Xia L, Lim SJ, Fan F, Mazar AP, Ellis LM.

Cancer. 2009 Jul 15;115(14):3360-8. doi: 10.1002/cncr.24371.

13.

The urokinase receptor as an entertainer of signal transduction.

D'Alessio S, Blasi F.

Front Biosci (Landmark Ed). 2009 Jan 1;14:4575-87. Review.

PMID:
19273372
14.
15.

The interaction between urokinase receptor and vitronectin in cell adhesion and signalling.

Madsen CD, Sidenius N.

Eur J Cell Biol. 2008 Sep;87(8-9):617-29. doi: 10.1016/j.ejcb.2008.02.003. Epub 2008 Mar 18. Review.

PMID:
18353489
16.

Evolving role of uPA/uPAR system in human cancers.

Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH.

Cancer Treat Rev. 2008 Apr;34(2):122-36. Epub 2007 Dec 26. Review.

PMID:
18162327
17.

The urokinase-system--role of cell proliferation and apoptosis.

Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, Arens N.

Histol Histopathol. 2008 Feb;23(2):227-36. doi: 10.14670/HH-23.227. Review.

PMID:
17999379
18.

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.

Knör S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, Kessler H, Senekowitsch-Schmidtke R, Magdolen V, Seidl C.

Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):53-64. Epub 2007 Sep 22.

PMID:
17891393
19.

uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells.

Lester RD, Jo M, Montel V, Takimoto S, Gonias SL.

J Cell Biol. 2007 Jul 30;178(3):425-36.

20.

Targeting uPA/uPAR in prostate cancer.

Li Y, Cozzi PJ.

Cancer Treat Rev. 2007 Oct;33(6):521-7. Epub 2007 Jul 19. Review.

PMID:
17658220

Supplemental Content

Support Center